Finance and funding

Finance and funding features

• 

  Will the world pay up to end HIV? Global AIDS funding

  We are at a critical point in the history of the HIV epidemic. We potentially have the tools to end it but, asks guest writer Laura...

  From:  HIV treatment update

• 

  Overhauling health: NHS reform, HIV and patient power

  The HTU guide to the NHS reforms, how they’ll affect you and how you can make the most of them. By Gus Cairns....

  From:  HIV treatment update

• 

  South African AIDS Conference: Special Issue

  The 5th South African AIDS Conference, held from 7-10 June, 2011 in Durban, showcased the recent remarkable achievements of the country’s HIV/AIDS response. Consequently, the conference was...

  From:  HIV & AIDS treatment in practice

• 

  The whether forecast: HIV services in the cutback era

  Some HIV experts are wondering not what our services will look like in the future but in some areas, whether there will be any HIV-specific services at all....

  From:  HIV treatment update

• 

  Whoever you vote for, the government gets in

  Lisa Power of the Terrence Higgins Trust (THT) looks at what voting for the three main political parties in the UK might bring for people with HIV and...

  From:  HIV treatment update

• 

  Making the money work harder: the new reality of HIV scale-up

  Doing more with less....

  From:  HIV & AIDS treatment in practice

• 

  Will the money drain out of AIDS?

  Earlier this year, on 25 February, the government of Botswana announced that if the global recession continued, it would have to freeze the provision of treatment for its...

  From:  HIV treatment update

Finance and funding news from aidsmap

• FDA Advisory Committee recommends accelerated approval of bedaquiline for drug-resistant TB

  Bedaquiline, the first agent in a new class of TB drug, has been recommended for accelerated approval by the Anti-Infective Drugs Advisory Committee of the United States Food and Drug Administration (FDA). The committee voted unanimously (18 to 0) ...

  03 December 2012 | Lesley Odendal

• Abacavir: new studies challenge the evidence of reduced potency when viral load is high

  An analysis of two studies of the new HIV integrase inhibitor dolutegravir presented at the Eleventh International Congress on Drug Therapy in HIV Infection in Glasgow had the incidental effect of bringing into question evidence from a previous study ...

  26 November 2012 | Gus Cairns

• PrEP probably cost effective in middle-income countries, but too costly to slash HIV incidence

  What is probably the most detailed and realistic modelling study so far done of the impact and cost-effectiveness of pre-exposure prophylaxis (PrEP) finds that it could be very cost-effective in terms of the price of an extra year of ...

  12 October 2012 | Gus Cairns

• First generic HIV drugs could save US at least $920 million a year

  Even using very conservative estimates of efficacy, using two generic HIV drugs plus one branded one in the most popular first-line regimen instead of using all three in a single-pill fixed-dose combination would save $4000 per quality-adjusted year of ...

  27 July 2012 | Gus Cairns

• Intellectual property “still a threat,” to antiretroviral access, says panel

  Patents and intellectual property restrictions continue to affect access to antiretroviral drugs, particularly in middle-income settings, according to research presented at the 19th International AIDS Conference (AIDS 2012) in Washington DC on July 25. While generic competition has ...

  26 July 2012 | Mara Kardas-Nelson

• Dramatic increases in life expectancy in a high-burden HIV setting due to ARV rollout

  The first evidence of dramatic changes in adult life expectancy in an HIV-endemic region, from individually measured data in a complete population cohort, showed large increases in adult life expectancy since the roll-out of antiretroviral (ARV) treatment. The survival benefits ...

  25 July 2012 | Lesley Odendal

• 'Global health charge' on alcohol and tobacco could cover HIV drug costs in 10 countries

  A modest increase in taxes on alcohol and tobacco in countries seriously affected by HIV and TB could generate enough income to cover the costs of antiretroviral treatment, TB treatment and malaria treatment and prevention, as well as reducing the ...

  24 July 2012 | Mara Kardas-Nelson

• They say we can “end AIDS”, but who will pay for it?

  With leaders from Mark Dybul to Michel Sidibé to Hillary Clinton to Anthony Fauci all saying that "we can end AIDS", the question is, who will pay for it? Speaking at a Monday session solely dedicated to financing the HIV ...

  24 July 2012 | Mara Kardas-Nelson

• Syringe exchange expansion in United States would be cost-saving

  According to a mathematical analysis presented at the 19th International AIDS Conference (AIDS 2012) in Washington, DC, providing clean syringes to reduce HIV transmission among Americans who inject drugs is considerably less expensive than treating the new cases of HIV ...

  24 July 2012 | Kelly Safreed-Harmon

• Providing HIV treatment to employees can lead to big savings for South African companies

  Provision of antiretroviral treatment through workplace health schemes in South Africa has the potential to save substantial sums for employers, as well as making a major contribution to treatment scale-up in the region, a new study presented at the 19th ...

  24 July 2012 | Keith Alcorn

More news

Finance and funding news selected from other sources

• Congress Cuts Funding For State ADAP Programs

  The failure of a US Senate spending bill to include $35 million in funding for HIV medications will jeopardize the ability of state AIDS Drug Assistance Programs to offer prescription drugs to nearly 8,000 low-income people living with the virus, according to patient advocates.

  10 hours ago | Pharmalot

• World Health Organization and Global Fund cite tuberculosis threat

  WHO and the Global Fund to Fight AIDS, TB and Malaria said today that strains of tuberculosis with resistance to multiple drugs could spread widely and highlight an annual need of at least US$ 1.6 billion in international funding for treatment and prevention of the disease.

  18 March 2013 | World Health Organization

• Uganda government under pressure to boost ARV funding

  The Ugandan government's draft 2013/2014 budget allocates US$38.5 million to enrol a further 100,000 people living with HIV on life-prolonging antiretroviral (ARV) drugs. But activists say the money, while welcome in a country still largely dependent on donor funds for its HIV programmes, is not sufficient to meet treatment needs.

  15 March 2013 | IRIN Plus News

• NHS in London spends £13m on PR

  The NHS in London spent almost £13m on public relations in the last three years, a BBC London investigation finds. Some trusts said PR spending was needed to educate the public on health issues. Yet the outlay on staff press officers was supplemented by millions of pounds handed to private PR firms.

  13 March 2013 | BBC Health

• Preventing HIV Infection With Anti-HIV Drugs in People at Risk Is Cost-Effective

  An HIV prevention strategy in which people at risk of becoming exposed to HIV take antiretroviral drugs to reduce their chance of becoming infected (often referred to as pre-exposure prophylaxis or PrEP), may be a cost-effective method

  13 March 2013 | Science Daily

• Viet Nam: HIV/AIDS fight faces cash crunch

  Viet Nam faces two major hurdles in combating HIV/AIDS: namely unsustainable achievements and the reduction of international financial support, says Minister of Health Nguyen Thi Kim Tien.

  11 March 2013 | VietNamNet Bridge

• Has HIV funding revived lagging health systems?

  The HIV/AIDS epidemic arrived in sub-Saharan Africa after decades of neglect had left healthcare systems dangerously weak, barely able to cope with the onslaught of patients. Then the money started pouring in. But the jury is still out on whether the large sums of AIDS funding have made healthcare systems more resilient.

  08 March 2013 | IRIN

• Funding Scientific Innovation: Global Investments in HIV Treatment Research and Development in 2010 and 2011

  The latest report found US$2.6 billion was invested in HIV treatment R&D in 2011. Data from 41 public, private, and philanthropic donors reveal a 12% increase in funding from the baseline year of 2009, with the majority of funding targeted at research for new medications.

  07 March 2013 | Treatment Action Group

• CROI 2013: Sequester Cuts Already Felt at Retrovirus Conference

  The 20th Conference on Retroviruses and Opportunistic Infections has officially ended, bringing to a close a four-day gathering of leading scientists whose work moves us closer to new tools for … Read More →

  07 March 2013 | BETA blog

• HIV 'cure' at risk from budget cuts

  The automatic cuts in federal spending known as sequestration could take a bite out of crucial medical research, such as the recently unveiled study in which a toddler was cured of HIV.

  06 March 2013 | CNN

More news